Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 7/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28707173 | 1.00 | PIK3CD (0.48) | PIK3CDPOLBDPP4CYP19A1PARP1 | |
| SCHEMBL18664136 | 0.80 | PIK3CD (0.65) | PIK3CDPOLBDPP4PARP1 | |
| SCHEMBL18664138 | 0.80 | PIK3CD (0.65) | PIK3CDPOLBDPP4PARP1 | |
| SCHEMBL18664137 | 0.80 | PIK3CD (0.65) | PIK3CDPOLBDPP4PARP1 | |
| SCHEMBL9739890 | 0.77 | POLB (0.36) | PIK3CDPOLBDPP4 | |
| SCHEMBL6545587 | 0.76 | PIK3CD (0.54) | PIK3CDPOLBDPP4GAA | |
| SCHEMBL25363257 | 0.76 | — | — | |
| SCHEMBL10563065 | 0.76 | — | — | |
| SCHEMBL10563056 | 0.76 | — | — | |
| SCHEMBL21322343 | 0.69 | PIK3CD (0.50) | PIK3CDPOLBDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360120-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2024-10-31 | — | — | US | disclosed |
| EP-3938358-B1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS INC (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-114072390-B | RAD51 inhibitors | 赛泰尔治疗公司 | 2024-06-11 | — | — | CN | disclosed |
| US-11932636-B2 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20220259198-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2022-08-18 | — | — | US | disclosed |
| US-11247988-B2 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-11247988-B2 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20200291014-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2020-09-17 | — | — | US | disclosed |
| US-20200291014-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2020-09-17 | — | — | US | disclosed |
| WO-2020186006-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. (US) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247988-B2 | RAD51 inhibitors | RAD51, MRE11, RAD54L | PIK3CD 2622/4885POLB 86/4885DPP4 4598/4885 |
| US-20220259198-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | PIK3CD 2622/4885POLB 86/4885DPP4 4598/4885 |
| US-20200291014-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | PIK3CD 2622/4885POLB 86/4885DPP4 4598/4885 |
| US-20240360120-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | PIK3CD 2622/4885POLB 86/4885DPP4 4598/4885 |
| US-11932636-B2 | RAD51 inhibitors | RAD51, MRE11, RAD54L | PIK3CD 2622/4885POLB 86/4885DPP4 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.